in

Clinical phase biopharmaceutical company: Anavex Life Sciences (AVXL) (2006)

Anavex Life Sciences Corp. (NASDAQ: AVXL) was founded in 2006 and is headquartered in New York with 13 full-time employees. It is a clinical-stage biopharmaceutical company whose main focus is on the treatment of Alzheimer’s disease, central nervous system diseases, pain and Various cancers.

Anavex Life Sciences Corporation AVXL Logo

Anavex Life Sciences (AVXL):

Anavex Life Sciences Corporation is a clinical-stage biopharmaceutical company mainly engaged in the development and research of biological Alzheimer’s disease, central nervous system diseases, pain and various cancer treatment drugs. The main drug candidates include:

  1. ANAVEX 2-73: Phase IIa clinical trial for Alzheimer’s disease has been completed; and it is in the treatment of Parkinson’s disease, Rett syndrome, epilepsy, infantile spasm, Fragile X syndrome, Angelman syndrome, and multiple sclerosis And the preclinical research phase of tuberous sclerosis.
  2. ANAVEX 3-71: Targeting the main characteristics of Alzheimer’s disease, gene transfer via Σ-1 receptor activation and M1 muscarinic ectopic regulation (3xTg-AD) in mice, an effective drug candidate with very small doses .
  3. ANAVEX 1-41: Σ-1 agonist for neuroprotective applications.
  4. ANAVEX 1066: A mixed Σ-1/Σ-2 ligand for the treatment of neuralgia and visceral pain.
  5. ANAVEX 1037: Treatment of prostate cancer and pancreatic cancer.
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all Intels

Specialty pharmaceutical company: Recro Pharma, Inc. (REPH)

IPO listing: bank holding company FVCBankcorp (FVCB)